Semax
- Category
- Brain & Cognition
- Administration routes
- Nasal
- Regulatory status
- Not FDA-approved
A synthetic peptide (an ACTH(4-10) analog) used intranasally as a nootropic and neuroprotective aid for stroke recovery and focus. Human evidence is moderate at best for stroke neuroprotection and raising BDNF, while cognitive claims rest on weak data. Nearly all studies run only 10 to 14 days, so long-term safety is unknown, and the FDA flagged immunogenicity. It is not an approved drug in the US, and most supply is unregulated research-grade material.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Semax is a synthetic seven-amino-acid peptide derived from ACTH (adrenocorticotropic hormone), a natural brain hormone, but engineered to keep only its brain-boosting properties while removing the hormonal effects. Developed in the 1980s at the Institute of Molecular Genetics of the Russian Academy of Sciences, its name comes from the Russian for 'seven amino acids.' Semax is approved in Russia as a prescription medication for ischemic stroke recovery, optic nerve diseases, and cognitive disorders, and is listed on Russia's essential drugs list. It is not FDA-approved. FDA's Pharmacy Compounding Advisory Committee reviewed it in July 2026: FDA's drug reviewers recommended against listing it and the committee voted in favor, as HHS's October 2026 policy records; FDA has not posted minutes or changed the list. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against limited compounding of semax nasal products under conditions; that is not an approval.
How it works in the body
A synthetic analog of ACTH(4-10) with a Pro-Gly-Pro extension. It increases BDNF and NGF expression in the brain, enhances dopaminergic and serotonergic neurotransmission, and modulates the expression of over 50 genes related to immune response and neuroplasticity. Does not affect cortisol despite its ACTH origin.
Research overview
Semax's primary mechanism is boosting BDNF (brain-derived neurotrophic factor) — a critical protein for forming new brain connections, learning, and memory that naturally declines with age. In rats, a single intranasal administration increased hippocampal BDNF protein by up to 40% and TrkB phosphorylation by 60%. It also activates dopamine and serotonin systems and has potent anti-inflammatory effects at the genetic level. In a trial of 110 ischemic stroke patients, two 10-day courses of Semax increased blood BDNF levels and accelerated functional recovery. A double-blind, placebo-controlled study in 30 healthy adults showed improved attention, working memory, and processing speed after a single dose. For Alzheimer's disease, preclinical studies show it prevents amyloid-beta clumping and reduced brain plaques 2.8-fold in transgenic mice. The evidence base is moderate to strong: extensive preclinical data with consistent results, plus several human trials predominantly from Russian institutions. The main gaps are the absence of large international trials and limited long-term safety data.
Who researches Semax?
Commonly researched by
People researching cognitive enhancement
Studied for neuroprotective effects, memory, or cognitive performance.
People researching immune system support
Studied for immune modulation, antiviral, or antimicrobial properties.
People researching inflammation management
Studied for anti-inflammatory effects across various conditions.
Important considerations for
Those with Acute psychosis or mania
HighSemax increases BDNF and dopaminergic activity, which may exacerbate psychotic or manic episodes.
Those who are pregnant or breastfeeding
AbsoluteNo reproductive safety data outside Russia.
Safety & interactions
Do not use if
Acute psychosis or mania
HighSemax increases BDNF and dopaminergic activity, which may exacerbate psychotic or manic episodes.
General cautions
Pregnancy
AbsoluteNo reproductive safety data outside Russia.
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(6)
Rated by level of concern
Most clinical studies examine only 10-14 day treatment courses
ModeratePMID 29798983 (dosing regimen)
FDA cited immunogenicity as a safety concern
ModerateFDA PCAC 503A bulk-substances review (July 2026, Docket FDA-2025-N-6895)
Mild nasal dryness/irritation (intranasal)
LowRussian clinical tolerability reports; product safety summaries
Occasional mild headaches
LowRussian clinical tolerability reports
Single-dose fatigue-study signal only for some claims
ModerateEvidence-base assessment across cited studies
Possible effects of chronically elevated BDNF
TheoreticalMechanistic inference (no Semax-specific human data)
Interaction summary(5)
Rated by direction with this peptide
Dopaminergic stimulants (amphetamines, methylphenidate, modafinil, bupropion)
CautionTheoreticalSemax activates dopaminergic transmission and experimentally potentiated d-amphetamine-induced dopamine release and locomotor activity in rodents, so additive CNS stimulation or overstimulation is plausible; no human clinical reports.
Eremin et al., Neurochem Res 2005;30(12):1493-1500 (amphetamine potentiation)
Serotonergic antidepressants (SSRIs/SNRIs, MAOIs)
CautionTheoreticalSemax modulates serotonergic metabolism (increased striatal 5-HIAA), giving a theoretical additive serotonergic effect; no documented interaction or serotonin-syndrome cases.
Eremin et al., Neurochem Res 2005;30(12):1493-1500 (serotonergic modulation)
Standard acute ischemic stroke therapy (thrombolytics/antiplatelets)
SynergisticLowStudied as a neuroprotective adjunct added to basic stroke therapy, where it accelerated functional recovery without a reported adverse interaction; complementary rather than harmful.
PMID 29798983
Opioid analgesics / endogenous enkephalin system
CautionTheoreticalThe C-terminal Pro-Gly-Pro extension is proposed to resist/inhibit enkephalin-degrading enzymes and prolong endogenous opioid peptides, so additive opioidergic effects with opioid analgesics are theoretically possible and warrant caution; purely mechanistic, not demonstrated clinically.
Mechanism: Pro-Gly-Pro enkephalinase resistance/inhibition
ACTH / corticosteroid (HPA) axis
NeutralTheoreticalDespite its ACTH(4-10) origin, Semax lacks corticotropic activity and does not raise plasma cortisol, so no HPA-axis or steroid-mediated interaction is expected.
Russian clinical pharmacology (no cortisol elevation)
Known risks(8)
Limited long-term safety data
Moderate (uncertainty)Most clinical studies examine 10-14 day treatment courses. No human studies have evaluated continuous Semax use beyond several weeks. While Ashmarin et al.'s 15-year review reported no adverse effects across all clinical applications, chronic safety including effects on melanocortin receptor systems, BDNF homeostasis, and neurotransmitter balance with prolonged use remains uncharacterized. The short half-life necessitates multiple daily doses, increasing cumulative exposure concerns.
Potential immunogenicity
ModerateThe FDA cited immunogenicity as a safety concern when placing Semax on the Category 2 list — the possibility that the body could perceive the peptide as a foreign substance and mount an immune response. While Semax is derived from an endogenous ACTH fragment and clinical studies have not reported allergic or anaphylactic reactions, the immunogenicity risk with repeated dosing in diverse populations has not been thoroughly evaluated in large trials.
Nasal irritation and dryness
LowThe most commonly reported side effect with intranasal administration. Mild nasal dryness, burning, or discomfort at the application site. Generally transient and self-limiting. It occurs more often early in treatment or at higher doses.
Mild headache
LowOccasional mild headaches reported, potentially related to neurotransmitter modulation effects on dopaminergic and serotonergic systems. Generally transient and resolve without intervention.
Potential increased anxiety at high doses
Low to ModerateOne trial in 16 healthy but fatigued individuals suggested that a single intranasal dose may have resulted in slightly elevated anxiety levels. This is likely related to Semax's stimulant-like effects at higher doses via dopaminergic activation.
Theoretical BDNF-related hair loss
Low (theoretical)Several studies exploring potential adverse effects of elevated BDNF levels have reported a possible link to increased hair loss in individuals predisposed to androgenetic alopecia. While Semax robustly enhances BDNF, the specific risk of this side effect remains uncertain and has not been confirmed in clinical studies of Semax specifically.
Pregnancy and lactation safety unknown
High (contraindicated due to insufficient data)Safety evidence is inadequate for pregnancy and lactation, which the Russian labels contraindicate. Pediatric use and studies exist, including specified indications for the 0.1% formulation in children aged seven and older; this does not establish safety across pediatric populations. Given its neurotrophic, immunomodulatory, and neurotransmitter-modifying properties, experts advise against use in pregnant or breastfeeding women until safety data is available. Semax has not been studied in patients with liver or kidney disease.
Research-grade purity concerns
ModerateOutside of Russia, most Semax available is unregulated products sold online, with unvalidated purity, potency, and sterility. Contaminants, incorrect concentrations, or degraded peptide pose risks when used for self-administration. Pharmaceutical-grade Semax is effectively only available through Russian pharmacies.
Drug interactions(6)
SSRIs and serotonergic drugs (fluoxetine, sertraline, citalopram)
Semax activates serotonergic brain systems and increases striatal serotonin metabolite (5-HIAA) levels to 180% of baseline (Eremin et al. 2005). Concurrent use with SSRIs, SNRIs, or other serotonergic drugs could theoretically produce excessive serotonergic stimulation. While no dangerous interactions have been documented clinically, caution is advised and patients should inform their prescriber of concurrent serotonergic medication use.
Psychostimulants (amphetamines, methylphenidate)
Semax dramatically enhanced D-amphetamine-induced dopamine release and locomotor activity in rodent studies (Eremin et al. 2005). This pharmacodynamic interaction could potentiate the effects and side effects of stimulant medications. Combined use should be monitored clinically, with attention to cardiovascular effects and overstimulation.
Dopaminergic drugs (L-DOPA, dopamine agonists, antipsychotics)
Semax modulates dopaminergic neurotransmission and significantly enhances dopamine release. Concurrent use with dopaminergic or anti-dopaminergic medications may produce additive or unpredictable effects on dopamine signaling. This is relevant for patients on Parkinson's medications or antipsychotics. Clinical significance is not fully characterized but monitoring is prudent.
Melanocortin receptor-active drugs
Semax acts as a competitive antagonist at melanocortin MC4 and MC5 receptors. It may interact with other melanocortin receptor ligands, including setmelanotide (MC4R agonist approved for obesity) or bremelanotide. Combined use could result in competitive antagonism and reduced efficacy of melanocortin-targeted therapies.
Blood pressure medications (antihypertensives)
Semax has been reported to enhance brain circulation and may have mild hemodynamic effects. Concurrent use with antihypertensive medications should be monitored for potential additive blood pressure lowering. Clinical data on this interaction is limited.
Other nootropic peptides (Selank, Noopept)
Using Semax with Selank adds Selank's anxiolysis through GABAergic modulation to Semax's cognitive stimulation through BDNF and dopaminergic pathways, and both peptides modulate overlapping neurotransmitter systems. While no adverse interactions have been documented, the combined neuropharmacological effects are not fully characterized in controlled clinical studies.
Research & benefits
Evidence base
- Evidence Level
- Moderate
- Total Studies
- 40
- Human Studies
- 8
Semax's clinical evidence base is moderate and geographically concentrated in Russian institutions. The primary human evidence comes from a clinical trial in 110 ischemic stroke patients showing Semax increased BDNF levels and improved functional recovery (Gusev et al. 2018); 15 years of clinical experience documenting cognitive enhancement in healthy volunteers with effects lasting 20-24 hours and no adverse effects (Ashmarin et al. 1997); a double-blind placebo-controlled study in 30 healthy adults showing improved attention, working memory, and psychomotor speed; and clinical trials demonstrating efficacy in optic nerve diseases including glaucomatous optic neuropathy (Polunin et al. 2000, Kurysheva et al. 2001). Preclinical evidence is substantially more extensive, with genome-wide transcriptomic studies, BDNF/neurotrophin pathway characterization, amyloid-beta aggregation inhibition, and melanocortin receptor pharmacology. Major gaps include the absence of large international RCTs, no long-term safety studies beyond 10-14 day courses, no trials specifically targeting aging or longevity outcomes, and publication of most Russian studies in Russian-language journals with limited international peer review.
Researched for(6)
Rated by confidence in the evidence
Neuroprotection and neuroregeneration in ischemic stroke
MediumAn approved stroke therapy in Russia, backed by human trials, though these are mostly open-label rather than blinded.
PMID 29798983 (Zh Nevrol Psikhiatr 2018); rat ischemia proteomics IJMS 2021 22:6179
Cognitive enhancement and nootropic effects
LowSupported by animal learning data and a clear BDNF mechanism, but controlled trials in healthy people are lacking.
Eremin et al., Neurochem Res 2005;30(12):1493-1500 (dopaminergic/serotonergic activation); Dolotov PMID 14556513
BDNF and neurotrophin upregulation for brain health
MediumExtensive animal data show raised BDNF and NGF, with elevated plasma BDNF confirmed in human stroke patients.
PMID 14556513; PMID 18756821; PMID 19662538; PMID 29798983
Protection against amyloid-beta neurotoxicity (Alzheimer's relevance)
SpeculativePreliminary, based on a single Alzheimer's mouse model showing reduced amyloid, with no human data yet.
Radchenko et al., Acta Naturae 17(4) 2025 (APPswe/PS1dE9 model)
Optic nerve protection and visual function improvement
LowSmall, open-label human studies report improved vision, supported by animal work and a neurotrophic mechanism.
PMID 10741256; PMID 11779410
Immune system modulation and neuroinflammation reduction
LowConsistent animal studies show reduced inflammatory signaling, but no human anti-inflammatory outcomes exist yet.
Medvedeva et al., BMC Genomics 2014 (PMC3987924); Mol Genet Genomics 2017 292:1215
Benefits(6)
Neuroprotection and neuroregeneration in ischemic stroke
Gusev et al. 2018 (Zh Nevrol Psikhiatr, PMID 29798983) — Trial in 110 ischemic stroke patients: two 10-day courses of Semax (6000 mcg/day) increased plasma BDNF levels, and combined with early rehabilitation, accelerated functional recovery and improved Barthel Index scores. Medvedeva et al. 2014 (BMC Genomics, PMC3987924) — Genome-wide analysis in rat focal ischemia showing Semax suppressed inflammatory genes and activated immune and vascular system genes, with immunoglobulin gene expression prominently elevated at 24 hours. Dmitrieva et al. 2009 (Cell Mol Neurobiol) — Semax activated transcription of BDNF, NGF, NT-3 and their receptors TrkA, TrkB, TrkC after cerebral ischemia in a coordinated time-dependent manner, supporting its success in acute stroke therapy.
Cognitive enhancement and nootropic effects
Ashmarin et al. 1997 (Zh Vyssh Nerv Deiat, PMID 9173745) — 15-year review documenting that intranasal Semax (0.015-0.050 mg/kg) significantly improved memory and attention in human subjects, with effects persisting 20-24 hours and no negative side effects reported. Double-blind placebo-controlled crossover study in 30 healthy adults showed improved attention, working memory, and psychomotor speed with 600 mcg intranasal Semax. Eremin et al. 2005 (Neurochem Res, PMID 16362768) — Semax activated dopaminergic and serotonergic brain systems in rodents, dramatically enhancing D-amphetamine-induced dopamine release and increasing striatal serotonin metabolite levels to 180%.
BDNF and neurotrophin upregulation for brain health
Dolotov et al. 2006 (Brain Research, PMID 16996037) — Single intranasal Semax (50 mcg/kg) produced 1.4-fold increase in BDNF protein, 1.6-fold increase in TrkB phosphorylation, threefold elevation of exon III BDNF mRNA, and twofold increase in TrkB mRNA in the rat hippocampus. Dolotov et al. 2006 (J Neurochem, PMID 16635254) — Semax showed specific, reversible, calcium-dependent binding to basal forebrain membranes (KD 2.4 nM, BMAX 33.5 fmol/mg protein) and produced rapid BDNF elevation in basal forebrain (but not cerebellum) after intranasal doses of 50-250 mcg/kg.
Protection against amyloid-beta neurotoxicity (Alzheimer's disease relevance)
Sciacca et al. 2022 (ACS Chem Neurosci, PMC8855339) — In vitro studies showed Semax prevents formation of Abeta:Cu2+ complexes, exhibits concentration-dependent anti-aggregating properties, inhibits fiber formation in buffer and membrane models, and protects cells from Abeta1-42 oligomer toxicity by up to 90%. Radchenko et al. 2025 (Acta Naturae, PMC12755871) — In APP/PS1 transgenic mice, Semax reduced cortical amyloid plaques 2.8-fold, improved cognitive functions in open field, novel object recognition, and Barnes maze tests, with effects persisting 1.5 months post-treatment. Primarily reduced small newly-formed plaques, suggesting inhibition of plaque formation.
Optic nerve protection and visual function improvement
Polunin et al. 2000 (Vestn Oftalmol, PMID 10741256) — Semax administered intranasally and by endonasal electrophoresis improved visual acuity, extended total visual field, increased electric sensitivity and conductivity of the optic nerve, and improved color vision in patients with vascular, toxic-allergic, and inflammatory optic nerve diseases. Kurysheva et al. 2001 (Vestn Oftalmol, PMID 11569188) — Complex neuroprotective therapy including Semax demonstrated advantages over traditional neuroprotective treatment in glaucomatous optic neuropathy patients with normalized ophthalmic tone, attributed to Semax's combined neuroprotective and neurotrophic activity.
Immune system modulation and neuroinflammation reduction
Medvedeva et al. 2014 (BMC Genomics, PMC3987924) — Genome-wide transcriptional analysis showed Semax most markedly affected immune response genes in ischemic brain, increasing expression of 51 immunoglobulin genes and chemokine genes at 24 hours post-stroke while modulating inflammatory cascades. Semax enhanced the amount and mobility of immune cells in ischemic tissue. The immunomodulating effects, combined with vascular system influences, represent key mechanisms underlying neuroprotective properties.
Key studies(10)
The efficacy of semax in the treatment of patients at different stages of ischemic stroke
Clinical trial110 patients (43 men, 67 women, mean age 58.0 +/- 9.7)Two 10-day courses of Semax 6000 mcg/day with 20-day interval; 5-month observationGusev EI, Martynov MYu, Kostenko EV, Petrova LV, Bobyreva SN
Zh Nevrol Psikhiatr Im S S Korsakova
2018
Semax administration increased plasma BDNF levels regardless of rehabilitation timing. Combined Semax and early rehabilitation produced accelerated improvement and ameliorated final Barthel Index outcome. Strong positive correlation between elevated BDNF levels and functional recovery measures. Motor performance improvements were most significant when Semax and early rehabilitation were combined.
A nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study)
Comparative study / 15-year reviewMultiple human and animal cohorts15 years of research, effects lasting 20-24 hours after single doseAshmarin IP, Nezavibat'ko VN, Myasoedov NF, Kamenskii AA, Grivennikov IA, Ponomareva-Stepnaia MA, Andreeva LA, Kaplan AYa, Koshelev VB, Riasina TV
Zh Vyssh Nerv Deiat Im I P Pavlova
1997
Comprehensive 15-year review documenting Semax's ability to stimulate operative memory and attention, increase resistance to hypoxia, and enhance brain circulation in both animal models and humans. Intranasal doses of 0.015-0.050 mg/kg significantly improved memory and attention in human subjects under demanding conditions. In no case did Semax produce negative side effects or complications across all clinical applications.
Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus
Original research (preclinical)Rats (multiple experimental groups)Single intranasal dose; 3-hour observationDolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, Dubynina EV, Novosadova EV, Andreeva LA, Alfeeva LYu, Kamensky AA, Grivennikov IA, Myasoedov NF, Engele J
Brain Research
2006
A single intranasal application of Semax (50 mcg/kg) produced a 1.4-fold increase of BDNF protein levels, 1.6-fold increase of TrkB tyrosine phosphorylation, threefold elevation in exon III BDNF mRNA, and twofold increase in TrkB mRNA in the hippocampus. Enhanced conditioned avoidance reactions confirmed cognitive effects. Demonstrates Semax modulates the hippocampal BDNF/TrkB system to affect cognitive function.
Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain
Original research (preclinical)Male Wistar rats; cultured astrocytesBDNF measured 3 hours post-treatmentDolotov OV, Karpenko EA, Seredenina TS, Inozemtseva LS, Levitskaya NG, Zolotarev YA, Kamensky AA, Grivennikov IA, Engele J, Myasoedov NF
Journal of Neurochemistry
2006
Semax demonstrated time-dependent, specific and reversible binding to basal forebrain cell membranes with high affinity (KD 2.4 nM, BMAX 33.5 fmol/mg protein) in a calcium-dependent manner. Intranasal Semax (50-250 mcg/kg) produced rapid BDNF elevation in the basal forebrain after 3 hours, but not in the cerebellum, suggesting regionally selective neurotrophic effects. Cognitive effects of Semax are associated with increased BDNF protein levels.
Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents
Research Support, Non-U.S. Government (preclinical)C57BL inbred miceObservations at 2 hours and 1-4 hours post-administrationEremin KO, Kudrin VS, Saransaari P, Oja SS, Grivennikov IA, Myasoedov NF, Rayevsky KS
Neurochemical Research
2005
Semax (0.15 mg/kg i.p.) significantly increased the extracellular striatal level of the serotonin metabolite 5-HIAA, which gradually rose to 180% within 1-4 hours. Semax alone did not alter baseline dopamine levels but dramatically enhanced D-amphetamine-induced dopamine release and locomotor activity. Demonstrates dual activation of dopaminergic and serotonergic neurotransmitter systems underlying nootropic properties.
The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis
Genome-wide transcriptional analysis (preclinical)Adult male Wistar rats (270-320 g); minimum 5 animals per time point3 hours and 24 hours following permanent middle cerebral artery occlusionMedvedeva EV, Dmitrieva VG, Povarova OV, Limborska SA, Skvortsova VI, Myasoedov NF, Dergunova LV
BMC Genomics
2014
Semax most markedly affected immune response genes in ischemic brain tissue. At 24 hours, over 50% of altered genes involved immune responses, with expression of 51 immunoglobulin genes increased. Chemokine gene expression was enhanced, and 24 vascular system genes showed altered expression at 3 hours. Immunomodulating effects combined with vascular system influences represent key mechanisms of neuroprotection in stroke.
Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia
Experimental animal research (in vivo)117 adult male Wistar rats in nine groups; minimum 5 animals per timepointObservations at 3, 24, and 72 hours following permanent MCAODmitrieva VG, Povarova OV, Skvortsova VI, Limborska SA, Myasoedov NF, Dergunova LV
Cell and Molecular Neurobiology
2010
Both Semax and its PGP fragment activate transcription of neurotrophins and their receptors in ischemic tissue. Semax enhanced expression of BDNF, TrkC, and TrkA genes early (3 hours post-occlusion) and NT-3 and NGF expression later (24-72 hours). The coordinated upregulation of both neurotrophins and their receptors during critical intervention windows likely explains Semax's clinical success in acute stroke therapy.
Semax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Models
In vitro experimental researchMultiple experimental conditions in triplicate; cell viability n=8 per conditionOligomerization assays 48 hours; cell treatment 48 hoursSciacca MFM, Naletova I, Giuffrida ML, Attanasio F
ACS Chemical Neuroscience
2022
Semax exhibited concentration-dependent anti-aggregating properties against amyloid-beta peptide. It prevented formation of Abeta:Cu2+ complexes, reduced oligomeric species levels, inhibited fiber formation in both buffer and membrane models, and protected cells from Abeta1-42 oligomer toxicity by up to 90%. Semax's anti-aggregation and neuroprotective properties were most pronounced in the presence of copper ions, a known contributor to Alzheimer's pathology.
The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease
Experimental animal research (transgenic mouse model)80 mice (60 APP/PS1 transgenic, 20 wild-type controls)~2.5 months treatment through 8.5 months of ageRadchenko AI, Kuzubova EV, Apostol AA, Mitkevich VA, Andreeva LA, Limborska SA, Stepenko YV, Shmigerova VS, Solin AV, Korokin MV, Pokrovskii MV, Myasoedov NF, Makarov AA
Acta Naturae
2025
Both Semax and its heptapeptide derivative improved cognitive functions in APP/PS1 mice across open field, novel object recognition, and Barnes maze tests. Semax reduced cortical amyloid plaques 2.8-fold, with effects persisting 1.5 months post-treatment (2.2-fold reduction). Primarily reduced newly-formed small plaques (less than 100 square micrometers), suggesting inhibition of plaque formation rather than clearance of existing deposits.
Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease
Clinical trial (comparative, controlled)Patients with optic nerve diseases (exact n not specified in English abstract)Acute and subacute treatment coursesPolunin GS, Nurieva SM, Baiandin DL, Sheremet NL, Andreeva LA
Vestn Oftalmol
2000
Semax, administered via intranasal drops and endonasal electrophoresis, effectively protected nervous tissue from aftereffects of injury during the acute stage of optic nerve disease. Treatment produced improved visual acuity, extended total visual field, increased electric sensitivity and conductivity of the optic nerve, and enhanced color vision perception across vascular, toxic-allergic, and inflammatory optic nerve conditions.
What research suggests over time
Weeks 2-4
Russian clinical useAcute alertness, focus, and stress-resilience effects within hours of intranasal dosing; sustained subjective improvements.
Months 2-3
Russian observationalBDNF elevation and sustained mood/cognitive improvements reported in Russian studies.
Long-term
Russian clinical useUsed clinically in Russia for stroke recovery and cognitive support. No Western Phase 3 trials.
Regulation & availability
Why researchers look at it
In rats, a single intranasal administration increased hippocampal BDNF protein by up to 40% and TrkB phosphorylation by 60%, while a trial of 110 stroke patients showed accelerated functional recovery and a double-blind study in 30 healthy adults improved attention and working memory. Preclinical Alzheimer's research showed a 2.8-fold reduction in brain plaques. Semax is registered in Russia. In the US, a draft interim HHS policy posted October 28, 2026 and open for public comment until mid-November names only single-ingredient nasal products made by licensed pharmacies for an individual prescription under conditions; it is enforcement discretion, not approval.
- Estimated cost
- No approved product and no verified reference price
- FDA status
- Semax is not FDA-approved. FDA identifies Semax among substances nominated but withdrawn, with continuing safety concerns. It is absent from current Category 1 and the positive 503A bulks list. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound semax (free base) for an individual patient's prescription under conditions that include: a single-ingredient nasal product made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. FDA's Pharmacy Compounding Advisory Committee reviewed Semax free base and acetate in July 2026; FDA's drug reviewers recommended against listing it and the committee voted in favor, as HHS's October 2026 policy records; FDA has not posted minutes or changed the list.
- WADA status
- Semax is not named on the 2026 WADA list. Its Russian therapeutic authorization means lack of FDA or EMA approval alone does not establish S0 prohibition. RUSADA explicitly listed Semax among nootropics allowed in sport in June 2023. Athletes should confirm its current status with their anti-doping organization.
- Prescribability
- Semax is not FDA-approved and is not on FDA's list of bulk substances pharmacies may use for compounding. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound semax (free base) for an individual patient's prescription under conditions that include: a single-ingredient nasal product made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. FDA's drug reviewers had recommended against listing Semax; FDA's Pharmacy Compounding Advisory Committee voted in favor in July 2026, as HHS's October 2026 policy records. Semax is registered in Russia as 0.1% and 1% nasal drops. The 1% formulation is indicated as part of treatment for moderate or severe acute ischemic stroke; the 0.1% label includes specified cognitive, cerebrovascular, optic-nerve, and pediatric indications. Peptic-ulcer treatment is studied use, not an indication in these labels. Other-country approvals were not verified. It is included on the Russian List of Vital and Essential Drugs.
- Availability
- Russia: registered nasal drops in 0.1% and 1% formulations, available as a prescription medication in pharmacies for treatment of ischemic stroke, optic nerve diseases, and cognitive disorders; the 1% formulation is used for acute stroke. Semax has been included on the Russian List of Vital and Essential Drugs since December 7, 2011. Other-country approvals were not verified. United States: no FDA-approved product, and not on FDA's compounding list. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound semax (free base) for an individual patient's prescription under conditions that include: a single-ingredient nasal product made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. FDA's Pharmacy Compounding Advisory Committee reviewed it in July 2026; FDA's drug reviewers recommended against listing it and the committee voted in favor, as HHS's October 2026 policy records; FDA has not posted minutes or changed the list. Europe and other markets: not approved as a medication. Pharmaceutical-grade Semax is difficult to obtain outside Russia, and unregulated products sold online have unvalidated purity.
International status
EU
Not approved
US
Semax is not FDA-approved and is not on FDA's list of bulk substances pharmacies may use for compounding. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound semax (free base) for an individual patient's prescription under conditions that include: a single-ingredient nasal product made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. FDA's drug reviewers had recommended against listing Semax; FDA's Pharmacy Compounding Advisory Committee voted in favor in July 2026, as HHS's October 2026 policy records.
Russia
Approved prescription medication since 1990s (nasal spray)
Regulatory timeline(15)
- 1980sSemax (Met-Glu-His-Phe-Pro-Gly-Pro) designed and synthesized at the Institute of Molecular Genetics of the Russian Academy of Sciences under the guidance of academicians I.P. Ashmarin and N.F. Myasoedov. Developed as a nootropic analog of ACTH(4-10) retaining neurotrophic activity without hormonal effects.
- 1991Semax first described in scientific literature by Potaman and colleagues, examining N-terminal ACTH(4-10) degradation by rat blood enzymes. Initial characterization of metabolic stability and pharmacokinetics.
- 1997Ashmarin et al. publish comprehensive 15-year review of Semax design and study, documenting nootropic efficacy in human subjects and lack of adverse effects (Zh Vyssh Nerv Deiat, PMID 9173745).
- 2000Polunin et al. publish clinical evaluation of Semax in optic nerve disease, demonstrating therapeutic efficacy via intranasal and endonasal electrophoresis routes (Vestn Oftalmol, PMID 10741256).
- 2001Kurysheva et al. demonstrate Semax's advantages over traditional neuroprotective therapy in glaucomatous optic neuropathy (Vestn Oftalmol, PMID 11569188).
- Early 2000sSemax approved by the Russian Ministry of Health and integrated into standard medical practice for ischemic stroke, traumatic brain injury, optic nerve diseases, and cognitive disorders.
- 2005Eremin et al. characterize Semax's activation of dopaminergic and serotonergic brain systems (Neurochemical Research, PMID 16362768).
- 2006Dolotov et al. publish two landmark papers: BDNF/TrkB regulation in hippocampus (Brain Research, PMID 16996037) and specific binding with BDNF elevation in basal forebrain (J Neurochem, PMID 16635254).
- 2011-12-07Semax included on the Russian List of Vital and Essential Drugs, approved by the Russian Federation government, solidifying its status as an essential medication.
- 2014Medvedeva et al. publish genome-wide transcriptional analysis of Semax effects in rat focal ischemia, revealing broad immune and vascular gene modulation (BMC Genomics, PMC3987924).
- 2018Gusev et al. publish clinical trial in 110 ischemic stroke patients demonstrating BDNF elevation and improved functional recovery with Semax (PMID 29798983).
- 2022Sciacca et al. demonstrate Semax's anti-aggregating properties against amyloid-beta and protection against copper-induced neurotoxicity in Alzheimer's models (ACS Chem Neurosci, PMC8855339).
- 2023-09FDA places Semax and 18 other peptide bulk drug substances on Category 2 interim list, effectively prohibiting compounding by 503A pharmacies in the United States.
- 2025Radchenko et al. publish Semax's efficacy in APP/PS1 transgenic Alzheimer's mouse model, showing 2.8-fold amyloid plaque reduction and cognitive improvement (Acta Naturae, PMC12755871).
- 2026-10-28HHS draft interim compounding policyHHS posts a draft interim, non-binding enforcement-discretion policy covering 503A compounding of semax (free base) under conditions (Federal Register Doc. 2026-22192, scheduled for Federal Register publication October 30, 2026; open for public comment until mid-November). Not an approval; not added to the 503A bulks list.
Sources & FAQs
Research sources(16)
- Gusev et al. 2018 — Semax efficacy in ischemic stroke, 110 patients (landmark clinical trial)
- Ashmarin et al. 1997 — 15-year review of Semax design and clinical study
- Dolotov et al. 2006 — Semax regulates BDNF and TrkB expression in hippocampus (Brain Research)
- Dolotov et al. 2006 — Semax binding and BDNF in basal forebrain (J Neurochem)
- Eremin et al. 2005 — Dopaminergic and serotonergic system activation (Neurochem Res)
- Medvedeva et al. 2014 — Genome-wide transcriptional analysis in focal ischemia (BMC Genomics)
- Dmitrieva et al. 2009 — Neurotrophin gene transcription after cerebral ischemia
- Sciacca et al. 2022 — Amyloid-beta aggregation and copper-induced neurotoxicity (ACS Chem Neurosci)
- Radchenko et al. 2025 — Semax in APP/PS1 Alzheimer's mouse model (Acta Naturae)
- Polunin et al. 2000 — Semax in optic nerve disease (Vestn Oftalmol)
- Kurysheva et al. 2001 — Semax in glaucomatous optic neuropathy (Vestn Oftalmol)
- Tsai 2007 — Hypothesis: Semax for ADHD and Rett syndrome (Medical Hypotheses)
- Semax — Wikipedia
- Alzheimer's Drug Discovery Foundation — Semax Cognitive Vitality Report
- FDA — Certain Bulk Drug Substances for Use in Compounding (Category 2 list)
- WADA 2026 Prohibited List
Frequently asked questions(6)
What is the difference between Semax and Selank?
Both Semax and Selank are synthetic heptapeptides developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, and both are approved medications in Russia. However, they have different parent molecules and primary effects: Semax is derived from ACTH(4-10) and is primarily a nootropic and neuroprotective agent that works through BDNF/neurotrophin upregulation and dopaminergic/serotonergic activation, while Selank is derived from the immunopeptide tuftsin and is primarily an anxiolytic with immunomodulatory properties that works through GABAergic modulation and cytokine regulation. Semax is indicated for stroke, cognitive disorders, and optic nerve diseases, while Selank is indicated for generalized anxiety disorder.
How quickly does Semax take effect?
Semax acts relatively quickly compared to many nootropic compounds. Ashmarin et al. reported that a single intranasal dose produced effects on memory and attention that persisted for 20-24 hours. Dolotov et al. (2006) showed that BDNF protein elevation in the hippocampus was detectable within 3 hours of a single intranasal dose. In clinical practice, users typically report subjective improvements in mental clarity and focus within 15-30 minutes of intranasal administration. The effects of individual doses are relatively transient due to the peptide's short half-life, which necessitates multiple daily administrations for sustained benefit.
Is Semax safe for long-term use?
Long-term safety data for Semax is limited. Clinical trials have examined only short treatment courses, and the approved Russian label involves short courses rather than continuous use. Ashmarin et al.'s 15-year review reported no negative side effects or complications across all clinical applications. The most common adverse effects are mild nasal irritation or dryness when used intranasally. No tolerance, dependence, or withdrawal has been documented. However, no human studies have examined continuous use beyond several weeks.
Can I get Semax in the United States?
Semax is not FDA-approved. It is absent from current Category 1 and the positive 503A bulks list. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound semax (free base) for an individual patient's prescription under conditions that include: a single-ingredient nasal product made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. Unregulated products sold online are outside the policy.
Does Semax have longevity or anti-aging benefits?
No direct lifespan extension studies have been conducted with Semax. However, Semax has several properties highly relevant to healthy brain aging: (1) it robustly elevates BDNF and NGF in the hippocampus and basal forebrain, supporting neuroplasticity and neurogenesis that decline with age; (2) it provides neuroprotection against ischemic brain injury, which becomes increasingly relevant as stroke risk rises with age; (3) it reduces neuroinflammation through genome-wide suppression of inflammatory gene expression, targeting a core driver of neurodegenerative disease; (4) it protects against amyloid-beta aggregation and reduces amyloid plaque burden in Alzheimer's disease models; (5) it activates dopaminergic and serotonergic systems, supporting neurotransmitter function that deteriorates with aging. These properties position Semax as a neuroprotective candidate for maintaining cognitive function during aging rather than a direct longevity agent.
Can Semax be taken orally?
No. As a peptide, Semax has poor oral bioavailability because it is rapidly degraded by enzymes in the gastrointestinal tract. The established clinical route is intranasal, which provides direct access to the central nervous system via the nasal mucosa and olfactory pathway, is non-invasive, and was used in the majority of clinical studies. FDA's review found no clinical literature supporting subcutaneous administration.